Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health (CADTH). Aripiprazole for pregnant women: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Respose - Summary of Abstracts. 2014 Authors' conclusions One non-randomized study was identified regarding the safety and harms of aripiprazole in pregnant women. Indexing Status Subject indexing assigned by CRD MeSH Antipsychotic Agents; Congenital Abnormalitiesnic and Fetal Development; Fetus; Maternal Exposure; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Teratogenss Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000826 Date abstract record published 30/06/2015 |